1 results match your criteria: "US National Cancer Institute and Health Sciences Administrator[Affiliation]"
Use of epidermal growth factor receptor mutation analysis in patients with advanced non-small-cell lung cancer to determine erlotinib use as first-line therapy.
PLoS Curr
June 2011
Program Director, CTEB, DCCPS, National Cancer Institute, NIH, Bethesda, MD; Institute of Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, WA; Physician, Health Services Researcher; Genomic Pharmacoepidemiology, US National Cancer Institute and Health Sciences Administrator, NCI, Bethesda, MD.
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in the United States. Moreover, advanced non-small-cell lung cancer (NSCLC) is considered an incurable disease and current treatment approaches provide marginal improvement in overall survival at the expense of substantial morbidity and mortality, highlighting the need for new, less toxic treatment approaches. Tyrosine kinase inhibitors, such as erlotinib (Tarceva®), have been developed and approved as maintenance, second- and third-line treatment options in unselected advanced NSCLC patients (2, 15).
View Article and Find Full Text PDF